Novartis AG ADR (NVS)vsRani Therapeutics Holdings Inc (RANI)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
RANI
Rani Therapeutics Holdings Inc
$0.88
+2.03%
HEALTHCARE · Cap: $107.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1785258% more annual revenue ($56.58B vs $3.17M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
RANI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+77.3%
Fair Value
$5.50
Current Price
$0.88
$4.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.76 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 28/100), backed by strong 23.9% margins. RANI offers better value entry with a 77.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is at the forefront of biotechnology innovation, transforming injectable therapies with its proprietary RaniPill™ technology that allows for oral delivery of biologics. This cutting-edge platform addresses significant patient adherence challenges, aiming to enhance treatment efficacy while meeting the rising demand for non-invasive therapeutic options. With a robust and diverse pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned to disrupt traditional drug delivery paradigms. The company's commitment to research and development, coupled with strategic collaborations, underpins its potential for significant growth and impactful contributions to the pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?